A Minimal PBPK Model for Plasma and Cerebrospinal Fluid Pharmacokinetics of Trastuzumab after Intracerebroventricular Administration in Patients with HER2-Positive Brain Metastatic Localizations-Reference-Cited by-同舟云学术

A Minimal PBPK Model for Plasma and Cerebrospinal Fluid Pharmacokinetics of Trastuzumab after Intracerebroventricular Administration in Patients with HER2-Positive Brain Metastatic Localizations

Published:2023-10-11 Issue:11 Volume:40 Page:2687-2697
ISSN:0724-8741
Container-title:Pharmaceutical Research
language:en
Short-container-title:Pharm Res

Author:

Puszkiel Alicja,Bousquet Guilhem,Stanke-Labesque Françoise,Stocco Jeanick,Decq Philippe,Chevillard Lucie,Goutagny Stéphane,Declèves Xavier^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s11095-023-03614-w.pdf

Reference45 articles.

1. Abouharb S, Ensor J, Loghin ME, Katz R, Moulder SL, Esteva FJ, et al. Leptomeningeal disease and breast cancer: The importance of tumor subtype. Breast Cancer Res Treat. 2014;146:477–86. Available from: https://link.springer.com/article/10.1007/s10549-014-3054-z.

2. Lazaratos AM, Maritan SM, Quaiattini A, Darlix A, Ratosa I, Ferraro E, et al. Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases. Breast. 2023;0. Available from: http://www.thebreastonline.com/article/S0960977623004502/fulltext.

3. Tan YO, Han S, Lu YS, Yip CH, Sunpaweravong P, Jeong J, et al. The prevalence and assessment of ErbB2-positive breast cancer in Asia. Cancer. 2010;116:5348–57. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.25476.

4. Thomas KH, Ramirez RA. Leptomeningeal disease and the evolving role of molecular targeted therapy and immunotherapy. Ochsner J. 2017;17:362.

5. Stemmler H-J, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs. 2007;18:23–8. Available from: https://insights.ovid.com/crossref?an=00001813-200701000-00004.